PDT Partners’s Celldex Therapeutics CLDX Stock Holding History

PDT Partners’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.01M	Sell	80,899 -16,923	-17%	-$547K	0.16%	198
2026 Q1	$3.1M	Hold	97,822	–	–	0.18%	183
2025 Q4	$2.66M	Hold	97,822	–	–	0.17%	207
2025 Q3	$2.53M	Hold	97,822	–	–	0.16%	221
2025 Q2	$1.99M	Buy	97,822 +76,923	+368%	+$1.5M	0.11%	299
2025 Q1	$379K	Buy	+20,899	New	+$467K	0.03%	569
2022 Q1	–	Sell	-16,327	Closed	-$631K	–	959
2021 Q4	$631K	Buy	+16,327	New	+$712K	0.05%	472
2017 Q2	–	Sell	-21,247	Closed	-$1.15M	–	522
2017 Q1	$1.15M	Sell	21,247 -3,373	-14%	-$176K	0.06%	302
2016 Q4	$1.31M	Sell	24,620 -3,933	-14%	-$224K	0.09%	302
2016 Q3	$1.73M	Sell	28,553 -4,474	-14%	-$279K	0.1%	243
2016 Q2	$2.17M	Buy	+33,027	New	+$2.1M	0.17%	192

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's CLDX Position: Q2 2026 in Review

PDT Partners reduced its Celldex Therapeutics (CLDX) stake by 17% in Q2 2026, selling an estimated $547K and leaving 80,899 shares worth $3.01M. The position accounts for 0.16% of the portfolio, ranked #198.

PDT Partners first reported a position in CLDX in Q2 2016 and has held it in 11 quarters since. The position peaked at $3.1M in Q1 2026. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

PDT Partners held 80,899 shares of Celldex Therapeutics worth $3.01M as of Q2 2026.
PDT Partners sold 16,923 Celldex Therapeutics shares in Q2 2026, an estimated $547K.
Celldex Therapeutics made up 0.16% of PDT Partners's portfolio in Q2 2026, its #198 holding.
PDT Partners first reported a position in Celldex Therapeutics in Q2 2016 and has held it in 11 quarters since.
PDT Partners's Celldex Therapeutics position peaked at $3.1M in Q1 2026.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.